Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 1.00 |
| ▸ | PGR | P06401 | 10/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039674 | 0.86 | AR (1.00) | ARPGRKDM4EALDH1A1MAPT | |
| SCHEMBL6651156 | 0.81 | AR (0.69) | ARPGRKDM4EALDH1A1MAPT | |
| SCHEMBL7023064 | 0.79 | AR (0.67) | ARPGRKDM4EALDH1A1MAPT | |
| SCHEMBL7032936 | 0.75 | AR (1.00) | ARPGR | |
| SCHEMBL15290656 | 0.71 | PGR (1.00) | ARPGRKDM4EALDH1A1MAPT | |
| SCHEMBL7038715 | 0.71 | AR (1.00) | ARPGR | |
| SCHEMBL2856726 | 0.69 | AR (0.91) | ARPGR | |
| SCHEMBL12476236 | 0.66 | KDM4E (0.51) | ARPGRKDM4EALDH1A1MAPT | |
| SCHEMBL27943851 | 0.66 | AR (0.48) | ARKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL7073759 | 0.64 | KDM4E (1.00) | ARPGRKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149268-A1 | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators | HAMANN LAWRENCE G (US) | 2003-08-07 | — | — | US | claimed |
| US-6667313-B1 | High affinity and specificity | LIGAND PHARMACEUTICALS INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030149268-A1 | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators | HAMANN LAWRENCE G (US) | 2003-08-07 | — | — | US | disclosed |
| EP-1212322-A2 | 8-SUBSTITUTED-6-TRIFLUOROMETHYL-9-PYRIDO[3,2-G]QUINOLINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016133-A2 | 8-SUBSTITUTED-6-TRIFLUOROMETHYL-9-PYRIDO[3,2-G]QUINOLINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149268-A1 | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators | AR, SHBG, NR5A1 | AR 1/4885PGR 32/4885KDM4E 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.